Qyuns Therapeutics Co Ltd (2509.HK)

HKD 11.24

(1.81%)

EBITDA Summary of Qyuns Therapeutics Co Ltd

  • Qyuns Therapeutics Co Ltd's latest annual EBITDA in 2023 was -484.12 Million CNY , down -55.63% from previous year.
  • Qyuns Therapeutics Co Ltd's latest quarterly EBITDA in 2024 Q2 was -80.43 Million CNY , down 0.0% from previous quarter.
  • Qyuns Therapeutics Co Ltd reported an annual EBITDA of -275.04 Million CNY in 2022, down -67.17% from previous year.
  • Qyuns Therapeutics Co Ltd reported an annual EBITDA of -149.45 Million CNY in 2021, down 0.0% from previous year.
  • Qyuns Therapeutics Co Ltd reported a quarterly EBITDA of -80.43 Million CNY for 2024 Q1, up 35.7% from previous quarter.
  • Qyuns Therapeutics Co Ltd reported a quarterly EBITDA of -145.15 Million CNY for 2023 Q4, down -24.34% from previous quarter.

Annual EBITDA Chart of Qyuns Therapeutics Co Ltd (2023 - 2021)

Historical Annual EBITDA of Qyuns Therapeutics Co Ltd (2023 - 2021)

Year EBITDA EBITDA Growth
2023 -484.12 Million CNY -55.63%
2022 -275.04 Million CNY -67.17%
2021 -149.45 Million CNY 0.0%

Peer EBITDA Comparison of Qyuns Therapeutics Co Ltd

Name EBITDA EBITDA Difference
Uni-Bio Science Group Limited 91.23 Million HKD 630.636%
CK Life Sciences Int'l., (Holdings) Inc. 486.79 Million HKD 199.45%